Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 21, 2025Frontiers in PharmacologyOpen Access

Dihydromyricetin attenuates age-related macular degeneration: pharmacological effects and exploration of putative targets

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHongyu ZhouJPJi PangBWBaiyang Wu

Discussion

Loading...

Member takes

Overview

Experimental evidence shows dihydromyricetin reduces AMD damage in cell and mouse models, suggesting potential pharmacological targets.

Key Points

  • Dihydromyricetin significantly mitigates age-related macular degeneration-induced damage in cellular and murine models, highlighting its therapeutic potential.
  • RT-qPCR results show that dihydromyricetin reverses abnormal biomarker expression associated with AMD, improving cellular health.
  • The study employed in vitro and in vivo methods, including molecular docking and network analysis, to explore dihydromyricetin's effects on AMD.
  • Findings suggest that dihydromyricetin may serve as a promising candidate for AMD treatment and warrant further exploration.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/68af5228ad7bf08b1eada0f3https://doi.org/10.3389/fphar.2025.1588970
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Online Mendelian Inheritance In Man (OMIM)2000 · 1,182 citations
  2. 2SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules2019 · 4,611 citations
  3. 3Disturbed Matrix Metalloproteinase Activity of Bruch's Membrane in Age-Related Macular Degeneration2011 · 88 citations
  4. 4Dihydromyricetin Attenuates Cerebral Ischemia Reperfusion Injury by Inhibiting SPHK1/mTOR Signaling and Targeting Ferroptosis2022 · 88 citations